Shire Targets Apotex Over Plan For Generic ADHD Drug

Law360, New York (November 25, 2013, 3:16 PM EST) -- Shire LLC accused generic-drug maker Apotex Inc. on Thursday of violating its intellectual property by seeking to sell a copy of Shire's attention deficit hyperactivity disorder drug Intuniv before the patents covering it expired.

The Apotex ANDA falsely states that Shire's two patents for guanfacine hydrochloride extended-release oral tablets, branded Intuniv, are invalid and unenforceable, according to Shire's complaint in the U.S. District Court for the District of Delaware.

"Apotex was aware of the existence of the [two patents] and acted without reasonable basis for believing...
To view the full article, register now.